Subscribe
  • Home
  • Issues
    • Latest Issue
    • Issue Archive
  • Browse By Topic
    • In the News
    • Practice Management
    • Biologics
  • Web Exclusives
    • Press Releases

Featured Articles

  • Updates on the Treatment of Atopic Dermatitis

    Updates on the Treatment of Atopic Dermatitis

    Atopic dermatitis, also known as eczema, is a common inflammatory skin condition that is characterized by dry, pruritic skin with a chronic relapsing course. Patients with atopic dermatitis may have to endure the social stigma of having a visible skin condition as well as intense itching that can lead to skin trauma and significant sleep disturbances, thereby adversely affecting quality of life. Researchers continue to study the safety and efficacy of novel agents for the treatment of atopic dermatitis, as well as patient- and disease-related factors that can affect patient outcomes.

    Read Article

  • Supporting Patient Access to Biologics Through Communication, Adherence, and Persistence

    Supporting Patient Access to Biologics Through Communication, Adherence, and Persistence

    Many types of biologics have been approved by the US Food and Drug Administration, including monoclonal antibodies (eg, adalimumab [Humira]), therapeutic proteins (eg, filgrastim [Neupogen]), and vaccines (eg, agents used for tetanus and influenza). In 2018, sales of biologics totaled approximately $125 billion, reflecting an increase of 50% from 2014 figures.1 Biologics coordinators play a central role in overcoming challenges to patient access to these agents by navigating benefits, communicating with insurance companies, and advocating for individual patients.

    Read Article

    In The News

    Updates on the Treatment of Atopic Dermatitis
    Supporting Patient Access to Biologics Through Communication, Adherence, and Persistence
    By Erin M. Burns, PhD, MSPH
    Ensuring Patient Access to Effective and Affordable Treatments Remains a Top Priority for the AAD
    View More Articles

    Biologics

    Supporting Patient Access to Biologics Through Communication, Adherence, and Persistence
    By Erin M. Burns, PhD, MSPH
    View More Articles

    Highlights From the Latest Issue:

    June 2020, Vol 1, No 1
    Read Issue
    Updates on the Treatment of Atopic Dermatitis
    Supporting Patient Access to Biologics Through Communication, Adherence, and Persistence
    By Erin M. Burns, PhD, MSPH
    Ensuring Patient Access to Effective and Affordable Treatments Remains a Top Priority for the AAD
    Providing Access to Practice Management Resources During the COVID-19 Pandemic: Ongoing Efforts of the ADAM

    Advocacy

    Advocacy
    Ensuring Patient Access to Effective and Affordable Treatments Remains a Top Priority for the AAD

    In an interview with Dermatology Practice Management (DPM), Bruce H. Thiers, MD, FAAD, President, American Academy of Dermatology (AAD), explains how the AAD, together with its sister organization, the American Academy of Dermatology Association (AADA), are working closely with federal, state, and local organizations to overcome access to care barriers for patients with dermatologic conditions.

    Read Article

    Practice Management

    Customer Service in Healthcare: The New Paradigm
    By Meg Barbor, MPH
    Evidence-Based Management: Better Decisions, Better Outcomes
    By Meg Barbor, MPH
    Providing Access to Practice Management Resources During the COVID-19 Pandemic: Ongoing Efforts of the ADAM
    View More Articles

    AAAAI Highlights

    Updates on the Treatment of Atopic Dermatitis
    View More Articles

    • Home
    • Issues
      • Latest Issue
      • Issue Archive
    • Browse By Topic
      • In the News
      • Practice Management
      • Biologics
    • Web Exclusives
      • Press Releases
    Subscribe
    • About
      • About DPM
      • Mission Statement
      • Contact
    • Contribute
      • Submit a Manuscript
      • Author Guidelines
    Sign Up for Dermatology News

    Subscribe to receive the free, monthly DPM print publication and DPM weekly e‑newsletter.

    Subscribe

    © Amplity Health. All Rights Reserved. Privacy Policy.